Ono Pharmaceutical Co Ltd - Company Profile
Powered by
All the data and insights you need on Ono Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Ono Pharmaceutical Co Ltd Strategy Report
- Understand Ono Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Ono Pharmaceutical Co Ltd patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
EP3902537A4 | Search Report | VERFAHREN ZUR BEHANDLUNG VON SWI/SNF-KOMPLEX-DEFIZIENTEM KREBS MIT GLUTATHION (GSH)-STOFFWECHSELWEGINHIBITOR | A61K31/197; A61K31/198; A61K31/439; A61K31/4402; A61K31/635; A61P35/00; G01N33/57484 | September 14, 2022 |
US20220283167A1 | Application | BIOMARKERS FOR DETERMINING THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS | G01N2333/70521; G01N33/57484 | September 08, 2022 |
US20220281977A1 | Application | BISPECIFIC ANTIBODY | A61K2039/505; A61P37/02; C07K16/2809; C07K16/2818; C07K16/46 | September 08, 2022 |
EP4048659A1 | Application | MODULATOREN DER KANALFUNKTION VON TREK (TWIK-VERWANDTE K+-KANÄLE) | C07D231/16; C07D401/04; C07D401/12; C07D401/14; C07D405/04; C07D405/06; C07D405/14; C07D409/14; C07D413/06; C07D413/14; C07D417/14; C07D471/04 | August 31, 2022 |
EP4048399A1 | Application | INHIBITOREN DER TREK (TWIK-ASSOZIIERTE K + KANÄLE)-KANALFUNKTION | A61P21/00; A61P21/02; A61P25/14; A61P25/16; A61P25/18; A61P25/22; A61P25/24; A61P25/28; C07C237/40; C07C237/42; C07C271/28; C07D213/75; C07D213/81; C07D241/20; C07D401/04; C07D401/06; C07D401/12; C07D405/12; C07D405/14; C07D409/04; C07D413/04; C07D413/12; C07D413/14; C07D417/12 | August 31, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer